Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Per M,Hellström

第一单位： Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

作者： Per M,Hellström ^[1] ; Eric,Gemmen ^[2] ; Heather A,Ward ^[2] ; Hyewon,Koo ^[3] ; Freddy,Faccin ^[4] ; Zhenyi,Xue ^[5] ; Petter,Malmborg ^[6]

作者单位： Department of Medical Sciences, Uppsala University, Uppsala, Sweden. ^[1] Epidemiology & Outcomes Research, IQVIA Real World Solutions, Cambridge, MA, USA. ^[2] Global Database Studies, Real World Solutions, IQVIA Solutions AB, Arenastaden, Sweden. ^[3] GMA Biotherapeutics, AbbVie Inc, San Juan, Puerto Rico. ^[4] Global Medical Affairs Statistics, Data and Statistical Sciences, AbbVie Inc, North Chicago, IL, USA. ^[5] Department of Clinical Science and Education, Karolinska Institute, Stockholm, Sweden. ^[6]

关键词 Crohn’s disease IBD TNF inhibitor biosimilar infliximab non-medical switch ulcerative colitis

主题词人类(Humans);胃肠病用药(Gastrointestinal Agents);抗体, 单克隆(Antibodies, Monoclonal);治疗结果(Treatment Outcome);炎性肠疾病(Inflammatory Bowel Diseases);慢性病(Chronic Disease);药物替代(Drug Substitution)

DOI 10.1080/00365521.2022.2090275

PMID 35833832

发布时间 2022-12-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交